Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epidemiological study on immune responses after third and fourth COVID-19 vaccine doses
jRCT1051210161Completed
- Start
- Jan 2022
- Countries
- 1
01
Overview
Open-label, single-arm trial in coronavirus disease 2019 (COVID-19). Primary endpoint: Humoral immune response. Started Jan 2022; status: completed.
02
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT1051210161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1051210161.